This is a routine post-annual-meeting 8-K with no material financial or operational content. The increased share reserve for equity compensation is standard and not immediately dilutive. Monitor the next earnings release for business momentum and potential equity grant activity.
Price Chart
Executive Summary
UroGen Pharma held its 2026 annual meeting of shareholders on June 22, 2026. Shareholders approved election of all 7 director nominees, amendments to the articles of association (tying shareholder proposals to Israeli Companies Law requirements), an amendment to the non-employee director and officer compensation policy regarding D&O insurance, and an amendment to the 2017 equity incentive plan increasing authorized shares by 1,000,000. All proposals received majority support. The filing is a routine post-meeting report with no financial data or business updates.
Key Facts
- Shareholders elected 7 directors to serve until the next annual meeting; all received substantial majority votes.
- Proposal 2 (Amended and Restated Articles) passed with 19,306,222 For vs 9,007,528 Against.
- Proposal 3 (Compensation Policy Amendment) passed with 26,089,418 For vs 2,182,017 Against.
- Proposal 4 (2017 Amended Plan) passed, increasing the share reserve by 1,000,000 shares to a total of 9,750,167 shares.
- Proposal 5 (advisory vote on executive compensation) passed with 25,125,846 For vs 3,186,040 Against.
- Proposal 6 (ratification of PricewaterhouseCoopers LLP as auditor) passed with 36,778,509 For vs 90,799 Against.
- No financial results, guidance, or business changes were disclosed in this filing.
Financial Impact
No financial impact disclosed in filing. The amendment to the 2017 Plan increases share authorization by 1,000,000 shares, but no awards were granted or priced.
Risk Factors
- Approved increase in authorized shares for equity plan could lead to future dilution if awards are granted aggressively.
- No business updates or financial guidance provided — filing offers no catalyst for near-term price movement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021442 |
| Exhibit: ex_979764.htm | 0001437749-26-021442 |
| Exhibit: ex_979763.htm | 0001437749-26-021442 |
| Document: urgn20260622_8k.htm | 0001437749-26-021442 |
| Document: 0001437749-26-021442-index-headers.html | 0001437749-26-021442 |
| Document: 0001437749-26-021442-index.html | 0001437749-26-021442 |
| Document: 0001437749-26-021442.txt | 0001437749-26-021442 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $45.00 $43.04 | ▼ −4.36% | ▼ −4.02% | $41.40 (−8.00%) |
Aug 20, 2026 6w ago | 8-K | $46.80 $45.50 | ▼ −2.78% | ▼ −3.89% | $41.40 (−11.54%) |
Aug 5, 2026 8w ago | 8-K | $46.43 $49.00 | ▲ +5.54% | ▲ +5.18% | $41.40 (−10.83%) |
Jun 23, 2026 14w ago | 8-K | $35.42 $37.94 | ▲ +7.11% | ▲ +5.41% | $41.40 (+16.88%) |
Jun 2, 2026 17w ago | 8-K | $26.54 $28.18 | ▲ +6.18% | ▲ +9.14% | $41.40 (+55.99%) |
May 6, 2026 21w ago | Press Release | $26.25 $29.80 | ▲ +13.52% | ▲ +12.39% | $41.40 (+57.71%) |
Apr 29, 2026 22w ago | Press Release | $23.34 $23.83 | ▼ −2.10% | ▲ +1.01% | $41.40 (−77.38%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.40 (+117.67%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.40 (+117.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access